SynthesisNature communications2024
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Open access · goldAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.Journal for immunotherapy of cancer · 2025Pooled it
- Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.Nature communications · 2024Pooled it
- First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.Cancer research communications · 2025Trial
- Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity.medRxiv : the preprint server for health sciences · 2026Article
- Article
- PGS Browser: a public platform for personalized polygenic score analysis and interpretation.Nature communications · 2026Article
- Epigenetic biomarkers in inflammatory bowel diseases-computational challenges and opportunities.Journal of Crohn's & colitis · 2026Review
- Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records.Cancer immunology, immunotherapy : CII · 2026Article
- Polygenic risk scores for Crohn's disease risk prediction in a Chinese population: insights from multi-ethnic genome-wide association studies.European journal of medical research · 2026Article
- Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements.iScience · 2026Review
- Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Case Report: Severe multi-organ damage induced by cadonilimab: mechanism investigation and management strategies.Frontiers in immunology · 2026Article
- Review
- Article
- Novel polygenic risk score associates with diverticulitis in a multi-institutional, ancestrally diverse cohort.Scientific reports · 2025Article
- Limited overlap between genetic effects on disease susceptibility and disease survival.Nature genetics · 2025Article
- Regulatory polymorphisms ofJournal for immunotherapy of cancer · 2025Article
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.Journal for immunotherapy of cancer · 2025Article
- Germline polygenic risk scores are associated with immune gene expression signature and immune cell infiltration in breast cancer.American journal of human genetics · 2024Article
- Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update.Journal for immunotherapy of cancer · 2024Review
Corrections and comments
- Update of
Authors and funding
28 authors at 5 institutions in 2 countries.
Pooja MiddhaDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5503-8215
Rohit ThummalapalliDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael J BettiDepartment of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-8394-6202
Lydia YaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Zoe QuandtDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Karmugi BalaratnamPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Cosmin A BejanDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-5107-0584
Eduardo CardenasDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Christina J FalconFiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David M FaleckGastroenterology, Hepatology & Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Princess Margaret Lung Group
Matthew A GubensDivision of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Scott HuntsmanDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-6390-773X
Linda KachuriDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3226-4727
Khaleeq KhanPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Min LiDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Christine M LovlyDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-3641-6361
Megan H MurrayDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-0131-2626
Devalben PatelPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Kristin WerkingDepartment of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Yaomin XuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Luna Jia ZhanPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Justin M BalkoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-4263-5974
Geoffrey LiuPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Melinda C AldrichDepartment of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-3833-8448
Adam J SchoenfeldThoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2644-1416
Elad ZivDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA. Elad.Ziv@ucsf.edu.ORCID http://orcid.org/0000-0002-2324-2884
Princess Margaret Cancer Centre · CAUniversity of California, San Francisco · USVanderbilt University Medical Center · USMemorial Sloan Kettering Cancer Center · USUniversity of Toronto · CA
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MPharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4MDiabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)K12DK133995 · NIDDK · STANFORD UNIVERSITY · PI LINDA A DIMEGLIO, David Matthew Maahs · 2022 to 2026
$16.0MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MUnderstanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0MThe Genetic Epemiology of Multiple SclerosisR01NS032830 · NINDS · VANDERBILT UNIVERSITY · PI HAINES, JONATHAN L · 1995 to 2010
$8.9MEpidemiologic Architecture for Genes Linked to Environment (EAGLE)U01HG004798 · NHGRI · VANDERBILT UNIVERSITY · PI CRAWFORD, DANA C · 2008 to 2013
$8.8MVESPA: Vanderbilt Electronic Systems for Pharmacogenomic AssessmentRC2GM092618 · NIGMS · VANDERBILT UNIVERSITY · PI DENNY, JOSHUA C., RODEN, DAN M · 2009 to 2010
$6.4MNCATS NIH HHS UL1 TR000445NCI NIH HHS K24 CA169004NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA227466NCI NIH HHS R01 CA227481NCI NIH HHS R01 CA251758NCI NIH HHS T32 CA009207NCI NIH HHS U01 CA253560NCI NIH HHS UG1 CA233259NCRR NIH HHS S10 RR025141NCRR NIH HHS UL1 RR024975NHGRI NIH HHS U01 HG004798NHGRI NIH HHS U01 HG006378NHLBI NIH HHS R01 HL156021NHLBI NIH HHS U19 HL065962NICHD NIH HHS R01 HD074711NIDDK NIH HHS K12 DK133995NIGMS NIH HHS P50 GM115305NIGMS NIH HHS RC2 GM092618NIH HHS S10 OD017985NINDS NIH HHS R01 NS032830
Abstract
Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn's disease (CD) and ulcerative colitis (UC) predisposes to IMC. In this study, we first develop a polygenic risk scores for CD (PRS
Indexed as
Carcinoma, Non-Small-Cell LungColitisColitis, UlcerativeCrohn DiseaseLung NeoplasmsGenetic Risk ScoreHumansImmune Checkpoint InhibitorsImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.